Data Insights

Ravulizumab LA by Alexion Pharmaceuticals for IgA Nephropathy (Berger's Disease): Likelihood of Approval

Ravulizumab LA is under clinical development by Alexion Pharmaceuticals and currently in Phase III for IgA Nephropathy (Berger's Disease). According...

Likelihood of Approval and Phase Transition Success Rate Model - Ravulizumab LA in IgA Nephropathy (Berger's Disease)

Data Insights

Efzimfotase alfa by Alexion Pharmaceuticals for Hypophosphatasia: Likelihood of Approval

Efzimfotase alfa is under clinical development by Alexion Pharmaceuticals and currently in Phase III for Hypophosphatasia. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Efzimfotase Alfa in Hypophosphatasia

Data Insights

Eculizumab by Alexion Pharmaceuticals for Subarachnoid Hemorrhage: Likelihood of Approval

Eculizumab is under clinical development by Alexion Pharmaceuticals and currently in Phase II for Subarachnoid Hemorrhage. According to GlobalData, Phase...

Data Insights

Danicopan by Alexion Pharmaceuticals for Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome): Likelihood of Approval

Danicopan is under clinical development by Alexion Pharmaceuticals and currently in Phase I for Atypical Hemolytic Uremic Syndrome (Nondiarrhea -...

Data Insights

Gefurulimab by Alexion Pharmaceuticals for Myasthenia Gravis: Likelihood of Approval

Gefurulimab is under clinical development by Alexion Pharmaceuticals and currently in Phase III for Myasthenia Gravis. According to GlobalData, Phase...

Data Insights

ALXN-2220 by Alexion Pharmaceuticals for Familial Amyloid Cardiomyopathy: Likelihood of Approval

ALXN-2220 is under clinical development by Alexion Pharmaceuticals and currently in Phase I for Familial Amyloid Cardiomyopathy. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - ALXN-2220 in Familial Amyloid Cardiomyopathy

Data Insights

ALXN-2220 by Alexion Pharmaceuticals for Amyloid Cardiomyopathy: Likelihood of Approval

ALXN-2220 is under clinical development by Alexion Pharmaceuticals and currently in Phase III for Amyloid Cardiomyopathy. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - ALXN-2220 in Amyloid Cardiomyopathy

Data Insights

ALXN-1920 by Alexion Pharmaceuticals for Kidney Disease (Nephropathy): Likelihood of Approval

ALXN-1920 is under clinical development by Alexion Pharmaceuticals and currently in Phase I for Kidney Disease (Nephropathy). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - ALXN-1920 in Kidney Disease (Nephropathy)

Data Insights

Vemircopan by Alexion Pharmaceuticals for Systemic Lupus Erythematosus: Likelihood of Approval

Vemircopan is under clinical development by Alexion Pharmaceuticals and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Vemircopan in Systemic Lupus Erythematosus

Data Insights

Vemircopan by Alexion Pharmaceuticals for Lupus Nephritis: Likelihood of Approval

Vemircopan is under clinical development by Alexion Pharmaceuticals and currently in Phase II for Lupus Nephritis. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Vemircopan in Lupus Nephritis

Data Insights

Vemircopan by Alexion Pharmaceuticals for Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease): Likelihood of Approval

Vemircopan is under clinical development by Alexion Pharmaceuticals and currently in Phase I for Membranoproliferative Glomerulonephritis Type II (Dense Deposit...

Likelihood of Approval and Phase Transition Success Rate Model - Vemircopan in Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease)

Data Insights

Vemircopan by Alexion Pharmaceuticals for IgA Nephropathy (Berger's Disease): Likelihood of Approval

Vemircopan is under clinical development by Alexion Pharmaceuticals and currently in Phase II for IgA Nephropathy (Berger's Disease). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Vemircopan in IgA Nephropathy (Berger's Disease)

Data Insights

Gefurulimab by Alexion Pharmaceuticals for Myasthenia Gravis: Likelihood of Approval

Gefurulimab is under clinical development by Alexion Pharmaceuticals and currently in Phase III for Myasthenia Gravis. According to GlobalData, Phase...